All In Biotech

Drug Trial Radar · NCT06927310

The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short Stature

A Multicenter, Randomized, Open-Label, Active-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Inpegsomatropin Injection, s.c Once a Week, Compared With Recombinant Human Growth Hormone (rhGH) Injection in Children With Idiopathic Short Stature (ISS).

Last checked: Nov 20, 2026Latest source record: Mar 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Apr 28, 2025

Primary completion

Mar 2026

Study completion Jun 2028

Sponsor

Sponsor type
Industry
Collaborators
Tongji Hospital
First posted
Apr 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 3 years, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, open-label, active-controlled Phase III clinical trial to evaluate the efficacy and safety of Inpegsomatropin injection,once a week,compared with recombinant human growth hormone (rhGH) in children with idiopathic short stature (ISS). It plans to enroll 300 children with ISS, who will be randomized , stratified by gender and age, and assigned to either the experimental group or the positive controlled group. Each participant will undergo a screening period (up to 12 weeks), a treatment period (52 weeks), and a post-treatment follow-up period (5 weeks). And the safety and efficacy will be evaluated.

Conditions

  • Idiopathic Short Stature

Interventions

  • Inpegsomatropin InjectionDrug

    Inpegsomatropin injection, 280 μg/kg/week, s.c., once weekly, for 52 consecutive weeks.

  • Recombinant Human Growth Hormone InjectionDrug

    Recombinant Human Growth Hormone Injection, 350 μg/kg/week, s.c., divided into 7 doses, i.e., 50 μg/kg/day (0.15 IU/kg/day), once daily for 52 consecutive weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Growth velocity (HV, cm/year).Time frame: Week 52

Locations

38 sites in 1 country. Site status is shown where the registry gives one.

  • Sanya Central Hospital

    Hainan, China · Recruiting

  • Hangzhou First People's Hospital

    Hangzhou, China · Recruiting

  • Zhejiang Provincial People's Hospital

    Hangzhou, China · Recruiting

  • The First Affiliated Hospital of Henan University of Science and Technology

    Henan, China · Recruiting

  • Jiaxing First Hospital

    Jiaxing, China · Recruiting

  • Affiliated Hospital of Jining Medical University

    Jining, China · Recruiting

  • Kunming Children's Hospital

    Kunming, China · Recruiting

  • Nanjing Children's Hospital

    Nanjing, China · Recruiting

  • Qingdao Women and Children's Hospital

    Qingdao, China · Recruiting

  • Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    Shanghai, China · Recruiting

  • Shanghai Children's Medical Center

    Shanghai, China · Recruiting

  • Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    Shanghai, China · Recruiting

  • The First Hospital of Hebei Medical University

    Shijiazhuang, China · Recruiting

  • Renmin Hospital of Wuhan University

    Wuhan, China · Recruiting

  • The Second Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, China · Recruiting

  • Xiangyang Central Hospital

    Xiangyang, China · Recruiting

  • The First Affiliated Hospital of Xinjiang Medical University

    Xinjiang, China · Recruiting

  • Yuncheng Central Hospital

    Yuncheng, China · Recruiting

  • Zhuzhou Central Hospital

    Zhuzhou, China · Recruiting

  • Anhui Provincial Children's Hospital

    Hefei, Anhui, China · Recruiting

  • The Second Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China · Recruiting

  • Capital Institute of Pediatrics, Beijing (SHOUER)

    Beijing, Beijing Municipality, China · Recruiting

  • Children's Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China · Recruiting

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China · Recruiting

  • Gansu Provincial Maternity and Child Care Hospital

    Lanzhou, Gansu, China · Recruiting

  • Guangzhou Women and Children's Medical Center

    Guangzhou, Guangdong, China · Recruiting

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China · Recruiting

  • The Third Affiliated Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China · Recruiting

  • Henan Children's Hospital Zhengzhou Children's Hospital

    Zhengzhou, Henan, China · Recruiting

  • Wuhan Children's Hospital

    Wuhan, Hubei, China · Recruiting

  • Hunan Children's Hospital

    Changsha, Hunan, China · Recruiting

  • Children's Hospital Affiliated to Soochow University

    Suzhou, Jiangsu, China · Recruiting

  • Jiangxi Provincial Children's Hospital

    Nanchang, Jiangxi, China · Recruiting

  • Children's Hospital of Shanghai

    Shanghai, Shanghai Municipality, China · Recruiting

  • Chengdu Women's and Children's Central Hospital

    Chengdu, Sichuan, China · Recruiting

  • West China Second University Hospital, Sichuan University

    Chengdu, Sichuan, China · Recruiting

  • The Affiliated Women's and Children's Hospital of Ningbo University

    Ningbo, Zhejiang, China · Recruiting

  • The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.